Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Abbott Vascular |
---|---|
Information provided by: | Abbott Vascular |
ClinicalTrials.gov Identifier: | NCT00402272 |
The purpose of this Clinical Evaluation is a continuation in the assessment of the performance of the XIENCE™ V Everolimus Eluting Coronary Stent System (XIENCE V™ EECSS) in the treatment of patients with de novo coronary artery lesions.
Condition | Intervention | Phase |
---|---|---|
Coronary Disease Coronary Artery Disease Coronary Restenosis |
Device: XIENCE V™ Everolimus Eluting Coronary Stent Device: TAXUS™ LIBERTÉ™ Paclitaxel Eluting Coronary Stent |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Single Blind (Subject), Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | SPIRIT V: A Clinical Evaluation of the XIENCE V™ Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions |
Estimated Enrollment: | 3000 |
Study Start Date: | November 2006 |
Estimated Study Completion Date: | November 2013 |
Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
XIENCE V™ Everolimus Eluting Coronary Stent System
|
Device: XIENCE V™ Everolimus Eluting Coronary Stent
Drug eluting stent implantation stent in the treatment of coronary artery disease.
|
2: Active Comparator
TAXUS™ Liberté™ Paclitaxel Eluting Coronary Stent System
|
Device: TAXUS™ LIBERTÉ™ Paclitaxel Eluting Coronary Stent
Drug eluting stent implantation stent in the treatment of coronary artery disease.
|
The SPIRIT V Clinical Evaluation consists of two concurrent studies,the Diabetic Study and the Registry. The study will be conducted in up to 150 study centers outside the United States. Approximately 3,000 patients will be enrolled in the study.
The SPIRIT V Diabetic Study is a prospective, randomized, active-controlled, single blind, parallel two-arm multi-center study comparing the XIENCE V™ EECSS to the TAXUS® Liberté™ in the treatment of diabetic patients with coronary artery lesions who will fulfill the eligibility criteria. Approximately 300 patients will be randomized (2:1) against the TAXUS® Liberté™ coronary stent system. These patients will be recruited in up to 40 selected sites.
The SPIRIT V Registry is a prospective, single arm, multi-center registry evaluating performance of the XIENCE V™ EECSS in real-world use, per its Instruction For Use (IFU). 2,700 patients will be enrolled in the SPIRIT V Registry.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
SPIRIT V Diabetic Study:
SPIRIT V Registry:
Exclusion Criteria:
SPIRIT V Diabetic Study:
Angiographic Exclusion Criteria of the Diabetic Study
SPIRIT V Registry:
Patient is already participating in another device or drug study or has completed the follow-up phase of another study within the last 30 days.
Principal Investigator: | Eberhard Grube, MD | The Heart Center, Siegburg, Germany |
Principal Investigator: | Upendra Kaul, MD | Fortis Hospital, New Delhi, India |
Responsible Party: | Matt Kiely ( Abbott Vascular ) |
Study ID Numbers: | 05-369 |
Study First Received: | November 17, 2006 |
Last Updated: | October 30, 2008 |
ClinicalTrials.gov Identifier: | NCT00402272 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
drug eluting stents stents Angioplasty coronary artery disease total coronary occlusion |
coronary artery restenosis stent thrombosis vascular disease myocardial ischemia coronary artery stenosis |
Everolimus Arterial Occlusive Diseases Heart Diseases Myocardial Ischemia Vascular Diseases Constriction, Pathologic Ischemia Arteriosclerosis |
Coronary Restenosis Coronary Stenosis Thrombosis Coronary Disease Coronary Occlusion Paclitaxel Coronary Artery Disease |
Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Therapeutic Uses Physiological Effects of Drugs Mitosis Modulators |
Tubulin Modulators Cardiovascular Diseases Antimitotic Agents Immunosuppressive Agents Antineoplastic Agents, Phytogenic Pharmacologic Actions |